ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1

At ADA 2026, findings from the Phase III TRIUMPH-1 trial were presented, assessing Eli Lilly's retatrutide in adults with obesity or overweight and at least one weight-related comorbidity.